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Abstract 
 
Antimicrobial peptide loaded poly(2-hydroxyethyl methacrylate) particles were synthesized 
in supercritical carbon dioxide via one-pot free-radical dispersion polymerisation of 2-
hydroxyethyl methacrylate and a cross-linker. Discrete particles with a well-defined spherical 
morphology and a diameter as low as 450 nm have been obtained in mild conditions. The 
encapsulation and release of the peptide were confirmed by antimicrobial tests that 
demonstrated for the first time a sustained release of the peptide from poly(2-hydroxyethyl 
methacrylate) microgels prepared by one-pot dispersion polymerization in supercritical 
carbon dioxide and then dispersed in water.   
Keywords: Encapsulation; microgel; antimicrobial peptide; supercritical carbon dioxide; 
polymers. 
1. Introduction  
 
Nowadays, an increasing number of therapeutic peptides and proteins are approved by the 
Food and Drug Administration (FDA), and many others are being developed at various stages 
including pre-clinical or clinical trials.[1] Historically, the importance of the proteins for human 
beings was highlighted by the human genome studies; most of genes were found to be 
responsible for protein encoding.[2] Having said the importance of proteins for human body, 
it was also revealed that they can be used as therapeutics to treat different kinds of diseases 
for instance genetic and degenerative disorders, protein malfunction and enzyme 
deficiencies. When the peptide/protein based drugs are compared to conventional drugs, 
they can be more active, may exhibit lower toxicity and weaker drug-drug interactions.[3] As 
an example, protein-based drugs offer momentary actions which make them safer than 
existing therapies such as gene therapy where random or permanent genetic alterations 
occurs.[4] Considering all the advantages of proteins, a vast number of studies turned to 
formulate active pharmaceutical ingredients based on peptides or proteins. However, 
peptides and proteins exhibit some drawbacks such as a rapid degradation or inactivation, a 
low bioavailability and a low permeability towards biological membranes.[5] Therefore, 
researches are focused on the idea of encapsulating them to increase their bioavailability, 
protect them from harsh environmental conditions and more importantly insure their 
controlled release over a course of time.[6]  
Among the valuable available peptides, one emerging family is the antimicrobial peptides 
(AMPs) developed to circumvent the global increase of antibiotic resistance and address the 
major infectious public health problems.[7] Roughly all types of Staphylococcus aureus 
species show resistance towards the conventional antibiotics such as penicillin and 
methicilin.[8] Therefore, to find solutions against the resistant bacteria holds a great 
importance in the research area. Studies focussing on the development of alternative 
antibiotic agents such as gene-coded AMPs are thus numerous.[9] Among them, temporins 
are short AMPs having up to 14 aminoacids which are derived from amphibians and showed 
high bactericidal efficiency. This group was named from the frog called Rana temporaria from 
which the AMP was initially extracted. Temporin A (TA) and Temporin L (TL) are active against 
Gram-positive bacteria, Candida species, fungi and have the ability to bind and permeate both 
artificial and biological membranes. TAs and TLs differ in the range of their antimicrobial 
activity as well as their toxicity. TLs were found to possess the strongest activity against fungi, 
Gram-positive and Gram-negative bacteria in comparison to other temporins. However, it 
was found that TLs were able to bind and permeate the membrane of mammalian cells 
(erythrocytes and cancer cells).[10] TLs are toxic on human erythrocytes thus necessitate for 
the synthesis of analogues. The amino acid sequence of the TL and its analogue Pro3TL is given 
below. Replacement of the Glutamine (Gln) residue in the third position with Proline (Pro) 
showed superior antimicrobial activity and lower haemolytic activity compared to native 
TLs.[11]  
                     TL: H-Phe1-Val2-Gln3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2 
            Pro3-TL: H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2 
 
Nevertheless, there is a need to encapsulate such AMP in order to control their release and 
time of action. Polymer network particles that have nano/micro scale size prepared by either 
physical or chemical cross-linking are referred as nano/microgels. These hydrogels were 
proven to be very promising candidates as drug carriers owing to their high loading capacity 
and stability.[12] Moreover, nano- or microgels hold a great promise due to their 
combinatorial properties between nanoparticles and hydrogels. They are highly hydrophilic 
and able to swell, whereas they have small size and large surface area as particles. 
Nano/microgels for protein/peptide delivery systems can be composed of either homo- or 
copolymers. 2-hydroxyethyl methacrylate (HEMA), ethylene glycol dimethacrylate (EGDMA), 
N-isopropyl acrylamide (NIPAAM), acrylic acid (AA) and methacrylic acid (MA) monomers are 
extensively used to form 3D polymer matrices. The polymer matrix will define the affinity for 
water whereas the cross-linking degree modulates the swelling of the network, therefore 
have an impact on the release behaviour of the encapsulated molecules.[3] Hydrogels of 
poly(HEMA) present excellent biocompatibility and can act as potential carriers in drug 
delivery, dental, ophthalmic, and neural tissue engineering applications.[13,14] Poly(HEMA) 
networks can be produced by free radical dispersion polymerization of HEMA monomer in 
the presence of a cross-linker and appropriate stabilizer. As previously mentioned, peptides 
and proteins have a sensitive structure which can be degraded easily by temperature and 
upon exposure to solvents leading to the loss of their activity. [4,15] In order to encapsulate 
them efficiently without altering their activity, a variety of production methods have been 
studied [16],[17]  including supercritical carbon dioxide processes. [18]  Supercritical carbon 
dioxide (scCO2) is a green alternative for the conventional solvents. It is non-toxic, non-
flammable and has low critical point (31.1°C and 73.8 bar).[19] More interestingly, scCO2 goes 
to gaseous state upon depressurisation which enables to produce formulations as dry 
powders offering better stability in comparison to liquid formulations. [18] 
Some of us have previously demonstrated the successful synthesis of cross-linked poly(HEMA) 
particles in supercritical carbon dioxide (scCO2) using mild conditions (35°C/300 bar) [20] and 
on their further redispersion and swelling in water thanks to the use of a fluorinated 
photocleavable stabilizer, i.e. poly(ethylene oxide) (PEO)-h-poly(heptadecafluorodecyl 
acrylate) (PFDA) (PEO-h-PFDA) block copolymer where h stands for a photosensitive 
moiety. This stabilizer was designed to perform dispersion polymerization in scCO2 leading to 
nanoparticles of poly(HEMA) that can swell in water after photolysis and removal of the 
fluorinated block.[21]  
The aim of this present work is to apply this process to the one-pot encapsulation of AMPs in 
cross-linked poly(HEMA) particles and to demonstrate the possible controlled release 
behaviour of the antibacterial peptide from the resulting nanogels. 
2. Experimental 
2.1 Materials 
All chemicals are purchased from Sigma-Aldrich and used as received unless otherwise it is 
noted. 2,2'-Azobis(4-methoxy-2,4-dimethylvaleronitrile) (V-70,Wako, 99%), 2-hydroxyethyl 
methacrylate (HEMA, Aldrich, 97%), Ethylene glycol dimethacrylate (EGDMA, Aldrich, 98%), 
Carbon dioxide (I5122,CO2 N27 purity > 99,999%, Air Liquide, Belgium), α,α,α -
Trifluorotoluene (TFT, Aldrich, 99+%). Ultrapure water was produced by MilliQ plus 188 
apparatus (Millipore). Bradykinin, Pro3TL and S. Aureus were kindly provided by the Symbiose 
Biomaterials. The photocleavable diblock copolymer used as stabiliser, PEO45-hv-PFDA40 was 
synthesized according to the previously published method by Alaimo et.al.[21]. 
2.2 Methods  
2.2.1 Synthesis of the poly(HEMA) particles in scCO2 
Dispersion copolymerisation of HEMA and EGDMA was performed as previously described by 
Parilti et al.[20], except that the peptide was added to the reaction medium. Briefly, the high 
pressure stainless steel cell (82 ml, ToP Industrie) was charged with 8.2 ml of HEMA (10% v/v 
CO2), 82 µl of EGDMA (cross-linker, 1% v/v monomer), 0.82 g of stabiliser (10% 
wstabiliser/Vmonomer), 0.187 g V-70 (1% w/v monomer) and 8.79 mg peptide (0.1% wBradykinin or 
wPro3Tl/wHEMA) and pressurized with CO2 at 300bar at 35°C and stirred for one night. After total 
depressurization, the cell was opened and the dry particles collected as a powder. Then, 
particles dispersed in TFT were subjected to 10 to 30 minutes of UV-irradiation using a UV 
lamp (LOT-Oriel Arc Light Source Hg(Xe), power = 500 W) to cleave the fluorinated block as 
quantified by XPS (for more details see ESI) and obtain water dispersible particles as reported 
by Alaimo et al. [21].  
2.2.2 Antibacterial Test 
For the quantification of the biocidal activity of the particles the following multiple step 
protocol has been applied as follows:  
1. A S. aureus preculture has been prepared by taking a few bacteria spread on a Luria-
Bertani agar gel (LBA), and placed in 10 mL of Luria-Bertani culture medium (LB) then 
incubated at 37 ° C overnight under agitation. Then, 2 ml of this solution was placed in 10 
ml of fresh LB at 37° C under stirring until the optical density at 600 nm is equal to about 
0.5;  
2. The samples to be tested (i.e. the free AMP, or 5 ml of the aqueous dispersion of  loaded 
or empty particles), were added with 4.5 mL of water and 0.5 mL of the bacterial solution; 
3. Then at each time t, 10 µL of solution was picked out and placed in a tube containing 10 
ml of LB culture medium; these tubes were placed on ice and then used for the drop plate 
method in order to count the colonies of viable bacteria. For this test, 3x 10μl were placed 
on an LBA gel putting the plates vertically so that the drops go down thanks to gravity. 
Once they were almost down, the plate was turned horizontally and incubated at 37°C for 
20 hours and then the bacteria colonies visible to the naked eye were enumerated. 
For these experiments, the LB solution was composed of 10g/L of Bactotryptone, 10g/L of 
NaCl and 5g/L of yeast extract. For the LBA solution, the composition was the same as for 
LB except that 15g/L of agar was added. 
2.3 Characterisation  
Particles were analysed by scanning electron microscopy (SEM, JEOL JSM 840-A) to evaluate 
their morphology. Samples were prepared on SEM stubs and coated with Pt (30 nm). The size 
distribution of particles in suspension in TFT (before UV) and in water (after UV) were 
measured by dynamic light scattering (DLS) using a Delsa Nano C, Particle Analyzer, Beckman 
Coulter at 25°C and the intensity of scattered light was detected at 165° to an incident beam. 
DLS measurements were done in triplicates in both TFT and water and each data set treated 
by the cumulant analysis.  
3.  Results and discussion 
3.1 Peptide loaded poly(HEMA) particles in scCO2 
In a previous work, cross-linked poly(HEMA) nanoparticles were prepared by dispersion 
copolymerisation of HEMA and a cross-linker (EGDMA) in scCO2 in mild conditions (35°C, 
300bar) with the aid of PEO-hv-PFDA photocleavable diblock copolymer stabilizer with an 
emerging optimal composition about PEO45-hv-PFDA40. Indeed, by using 10% of this stabilizer, 
regular poly(HEMA) particles with a size as small as 279nm are obtained (Table 1, entry 1) 
while a size of 400nm is reached by decreasing the stabilizer content to 5% (Table 1, entry2). 
Therefore, for the one-pot encapsulation of the guest peptide, the Bradykinin or the Pro3TL 
were introduced to this original reaction mixture (Table 1, entries 3-5) following the 
experimental set-up depicted in Figure 1.  
 
Figure 1: synthesis of the antimicrobial peptide (AMP)-loaded particles by one-pot dispersion 
polymerisation of HEMA in scCO2. Left: scheme of the high-pressure stainless steel cell which is filled 
with the HEMA monomer (8.2 ml, 10% v/v CO2), the EGDMA cross-linker (16.4 µl, 2.5% v/v monomer), 
the PEO45-hv-PFDA40 stabiliser (0.41 mg, 5% w/w monomer), the V-70 initiator (0.187 g, 1% w/v 
monomer), the AMP Pro3TL (8.79 mg, 0.1% w/w monomer) and the CO2 (P=300bar, T=35°C). Right: A 
picture of the dry powder obtained after 12h of polymerization and complete depressurization of the 
cell and a scanning electron microscopy image of this powder (scale bar: 3µm) 
Table 1: Characteristics of the synthesized poly(HEMA) particles 
 
Monomer 2-hydroxyethyl methacrylate (8.2 ml, 10% v/v CO2) and initiator V-70 (0.187 g, 1% w/v 
monomer) concentration and reaction conditions (35°C/300 bar) were kept constant.  a: Cv stands for 
the coefficient of variance which is calculated according to the equation (Standard Deviation/Dn)*100 
applied to SEM data,  b: Bimodal distribution. c: hydrodynamic diameter: average size on triplicates  
Entry Stabiliser EGDMA  Bradykinin Pro3TL SEM               Dhc by DLS 
 (%,wt) (%, v) (%, wt) Dn 
(nm) 
Cva in TFT 
before UV  
in water 
after UV  
1 10 1   279 9 461 nm 4.1 µm 
2 5 1   404 12 1.10 µm 4.4 µm 
3 10 1 0.1  316 43b 771 nm 3.2 µm 
4 10 2.5 0.1  436 34b 639 nm  3.0 µm 
5 5 2.5  0.1 432 8 700 nm 3.8 µm 
With the purpose to evaluate the impact of the presence of the peptide on the dispersion 
polymerisation reaction in scCO2, Bradykinin a model peptide readily available and presenting 
no bactericidal activity has been firstly used, then Pro3TL, the active antibacterial peptide, was 
introduced to the reaction mixture for encapsulation.  
Initially, Bradykinin loaded particles were synthesized with two cross-linker concentrations 
(1% and 2.5 %) using 10 wt % stabiliser. Although particles were obtained with well-defined 
morphology, they had a bimodal distribution which was clearly evidenced by SEM images 
(Figure S1: Entries 3 and 4) and confirmed by very high Cv number (Table 1). Bradykinin was 
found to have a low solubility in HEMA, therefore some phase separations could explain this 
large dispersity. On the other hand, the one-pot encapsulation of Pro3TL was carried out in 
the presence of 5 wt% of the PEO45-hv-PFDA40 stabiliser. At the end of the polymerisation, 
monodisperse spherical particles with 432 nm diameter were harvested as a dry fine powder 
(Figure 1). The presence of the peptide in the medium did not appear to affect the particles 
formation and size. In that case, the cross-linker content was also set to 2.5% in order to get 
a denser network to sufficiently trap the peptide inside the particles and insure a controlled 
release. 
In order to remove the fluorinated block from the particles surface, they were dispersed in 
TFT and irradiated by UV. As previously reported, the UV-photolysis of the nitrobenzyl group 
at the blocks junction leads to the release of 57% of the hydrophobic block (PFDA) of the 
stabiliser in the TFT solution when the irradiation is kept for 30min. [21] This percentage of 
the extracted PFDA was confirmed by XPS measurements (ESI). In case of peptide loaded 
particles, the irradiation time was reduced to 10 min. to prevent photodegradation of the 
peptide. In that case, a release of 41% of the PFDA block was determined by XPS. This partial 
removal of PFDA was sufficient to allow the particles dispersion and swelling in water. Indeed, 
as demonstrated by DLS measurements performed in water (Table 1, after UV), all the 
particles showed a significant size increase upon swelling in water as compared to the dry 
state (Table 1, SEM) or to TFT, a non-solvent of poly(HEMA) (Table 1, before UV) resulting in 
hydrogel particles of 3-4µm.   
3.2 Antibacterial tests on empty and loaded particles 
 
In order to determine the potential of this encapsulation strategy, the bactericidal behaviour 
of the particles loaded with Pro3TL have been evaluated against Staphylococcus Aureus and 
compared to the behaviour of empty particles. Some preliminary tests were first performed 
to validate the test and collect references. A first reference sample was performed by 
incubating the bacteria in water without particles. The number of remaining viable bacterial 
colonies was counted at regular time intervals and are reported in Table S1. This test confirms 
that the bacterial strains are able to multiply in aqueous medium in which the number of 
bacterial colonies is very large (Uncountable colonies (UC)). Similar behaviours are obtained 
when the bacteria are incubated with bradykinin, this peptide having no bactericidal effect. 
In contrast, an immediate and complete killing of the bacteria is observed when the free 
Pro3TL peptide is incubated with the bacteria whatever its concentration (6.25 or 12.5 µg/ml). 
Then, empty particles obtained from Table 1 entry 1 after removal of the fluorinated block by 
irradiation of the particles in TFT were incubated at two concentrations with the bacteria 
(Table S2 and Figure 2). Note that in the Figure 2 which reports the same data as Table S2, an 
arbitrary number of colonies of 120 was selected when the number of colonies are impossible 
to count because they are too many (UC in Table S2 means that there is no bactericidal effect). 
These empty particles at both concentrations did not present any bactericidal behaviour for 
24 hours meaning that the particles themselves do not lead to an antibacterial effect. This is 
also confirmed by using bradykinin-loaded particles. Regardless of the concentration, 
Bradykinin loaded particles (Table 1: Entry 3 and 4) showed similar behaviour as empty 
particles which did not present any bactericidal effect for 24 hours (Table S2 and Figure 2). 
This first set of tests evidenced that the encapsulation carrier as produced by the scCO2 
process does not exhibit any effect on the bacteria growth and proliferation. Then, the 
particles loaded with ~0.1% of Pro3-TL (Table 1, entry 5) were incubated at two 
concentrations, i.e. 56 mg and 112 mg of particles. The first assays (Test 1) for antibacterial 
tests were performed right after the irradiation and removal of the fluorinated segments 
(Table S2 and Figure 2).  
When a low concentration of the particles loaded with Pro3-TL (56 mg of particles, thus ~5,6 
µg/mL of AMP) is incubated with the bacteria, no bactericidal effect is observed after 24h in 
strong contrast to free Pro3-TL which immediately kills the bacteria already at a concentration 
of 6.25 µg/mL (Figure 2). This evidences that the AMP is well encapsulated in the particles 
and is released slowly during the first 24h so that no bactericidal concentration is reached for 
this period. A deactivation of the peptide could also account for this loss of activity but 
doubling the concentration of particles to 11,2 mg/ml (~11,2 µg/mL of AMP) against the same 
amounts of bacteria led to a clear recovery of the bactericidal effect after 1 hour which 
becomes significant after 4 hours of release evidencing the gradual release of the active 
peptide from the nanogel particles. The incubation time was extended till 24 hours leading to 
further release of the peptide and allowed the complete killing of the bacteria after 5h (Figure 
2). This proves that the encapsulated peptide is still active, and able to diffuse slowly out of 
the particles to reach a minimal concentration in solution leading to the bactericidal effect. 
These data show for the first time that the developed process allows an efficient 
encapsulation of the peptide while keeping its bactericidal activity, and its sustained release 
from the particles.  
 
Figure 2: Bactericidal test against Staphylococcus Aureus incubated with free Pro3TL 6.25µg/ml (circle), 
empty particles 11.2mg/ml (square), and Pro3TL-loaded particles 5.6 mg/ml (diamond) or 11.2mg/ml 
(triangle) performed directly after synthesis and UV irradiation of the particles (Test 1). When the 
number of colonies is uncountable because they are too large (no bactericidal effect), an arbitrary 
value of 120 was chosen in this figure. 
 
A second run of assays was performed after storing the dry particles at room temperature for 
10 days after UV treatment (Test 2) (Figure 3A, Table S3). In this test 2, the concentration of 
particles has been doubled, i.e. 11.2 mg/ml and 22.5 mg/ml, as compared to test 1 to 
accelerate the biocidal effect. Figure 3A further confirmed the gradual release of the 
encapsulated Pro3-TL from the nanogel particles for both concentrations (11,2 mg/ml and 
22,5 mg/ml). As the concentration of the particles increases (from 11,2 mg/ml to 22,5 
mg/ml),the amount of released peptide in the same period of time is increased and leads to 
faster bactericidal effect. 
A       B 
            
Figure 3: Bactericidal test against Staphylococcus Aureus incubated with Pro3TL-loaded particles A) 
after 10 days of particles storage, particles concentration of 11.2 mg/ml (diamond) and 22.5 mg/ml 
(square) (Test 2) B) after 2 months of particles storage, particles concentration of 22.5mg/ml (Test 3). 
When the number of colonies is uncountable because they are too large (no bactericidal effect), an 
arbitrary value of 120 was chosen in this figure. 
 
Complete killing of the bacteria is observed between 5 to 6 hours of incubation time for the 
highest concentration (22,5 mg/ml, ~22,5 µg/mL of AMP ) while more than 7h of incubation 
is required for the lower concentration (11.2µg/ml of AMP). Nevertheless, after 24 hours of 
release, all the bacteria are killed even at the lower concentration.  
Comparing tests 1 and 2 (Figure 2 and 3A) with the same number of particles, the kinetics of 
release appears slower in the test 2 performed after 10 days of storage. Therefore, a third 
test was performed in triplicates after 2 months of storage of the particles in the dry state in 
glass vial at room temperature. The results of this test 3 are reported in Figure 3B and table 
S4 and indicate that the bacteria are still proliferating after 24h for the lowest concentration 
(11,2mg/ml particles, ~11,2 µg/mL of AMP), and that the kinetic tests performed 
simultaneously are reproducible, regardless of the quantity of microgels. In the case where a 
larger amount of microgels is used (22,5mg/ml, ~22,5 µg/mL of AMP), the decrease in the 
number of bacterial colonies is progressive with a population number equals to zero after 24 
hours of release. Nevertheless, once again, the bactericidal effect appears after a slightly 
longer time period than in the previous tests 1 and 2 performed with the same batch of 
particles but at early stages after their preparation. From these measurements, we can 
conclude that the peptide is well encapsulated in the particles which control its release. 
Nevertheless, it appears that the peptide stability and/or its release rate is affected by the 
prolonged storage of the particles. Further studies will have to be done to clarify the origin of 
this phenomenon. Nevertheless, the complete killing of the bacteria is still observed for 24h 
of release for a storage time of 2 months showing the sustained release of the AMP thanks to 
the developed encapsulation process. 
4 Conclusions 
In this work, we reported a novel, facile process for the encapsulation of antimicrobial peptide 
in well-defined spherical poly(HEMA) cross-linked particles via one-pot free radical dispersion 
polymerization carried out in scCO2. Based on previous studies [20],[21], peptide loaded 
poly(HEMA) particles were successfully synthesized in the presence of PEO45-hv-PFDA40 using 
mild conditions (35°C/300 bar). At low concentration of stabilizer (5%wt), discrete 
monodisperse peptide loaded poly(HEMA) particles could be easily obtained with a size of 
400nm. After only 10 min. of UV treatment of these particles, the fluorinated block of the 
stabilizer could be partially extracted and the particles could be redispersed and swollen in 
water, resulting into micron-sized hydrogels which was evidenced by DLS measurements. The 
antibacterial tests revealed the sustained release of the AMP from these poly(HEMA) particles 
swollen in water. In contrast to free AMP, the antibacterial effect was delayed which confirms 
the efficient encapsulation of the AMP. The robustness of the developed one-pot 
encapsulation method was proven even if a slight decrease of the bactericidal efficiency was 
observed for prolonged storage time. However, concrete hypothesis could not be drawn with 
respect to data in hand and would require further investigations beyond the scope of this first 
study. We believe that this study opens a pathway to encapsulate the active pharmaceutical 
ingredients that are heat and solvent labile especially such as peptides in mild conditions using 
scCO2 as a green polymerisation medium.  
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